Potential Lung Cancer Drug from Incyte and Novartis to Get a Priority Review from FDA
Patients with a particularly aggressive form of lung cancer could have a new, easy-to-swallow treatment option this summer called capmatinib. The first New Drug Application for the experimental treatment, which Novartis (NYSE: NVS) licensed from Incyte (NASDAQ: INCY), will receive a priority review from the FDA that will shave at least four months off the decision-making process.
After Incyte completed a phase 1 clinical trial of capmatinib in 2012, Novartis took control of the drug's development. While it doesn't seem like Novartis was in a rush to send in its application to the FDA, capmatinib could jump straight to the head of the class as a treatment for patients with MET exon 14 skipping (METex14) mutated non-small cell lung cancer.
Image source: Getty Images.
Source Fool.com
